Scipher Medicine to Participate in Truist Securities Life Sciences AI Symposium

Feb 28, 2022

WALTHAM, Mass. (Feb. 28, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced Chief Technology Officer Slava Akmaev, Ph.D., will participate in a virtual panel at the Truist Securities...

Scipher Medicine Closes $110 Million Financing

Feb 24, 2022

Cowen Healthcare Investments leads the round Additional new investors include Neuberger Berman, Hitachi Ventures, Laurion Capital, and Monashee Investment Management Returning investors include Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo...

Scipher Medicine to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Feb 11, 2022

WALTHAM, Mass. (Feb. 11, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Chief Financial Officer John Strumbos will participate in the virtual 11th Annual SVB Leerink...

Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA Blood Test

Feb 1, 2022

Patient Response to Treatment 3x Better When PrismRA Guided Therapy Selection Test Results Informed Treatment Decisions for Three-Quarters of Patients Broad Adoption Could Lead to Significant Clinical Improvements for Rheumatoid Arthritis Patients WALTHAM, Mass. (Feb....

Scipher Medicine Leadership to Present at the 40th Annual J.P. Morgan Healthcare Conference

Jan 6, 2022

WALTHAM, Mass. (Jan. 6, 2022) - Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Alif Saleh, chief executive officer, will present at the 40th Annual J.P. Morgan...

Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis

Dec 30, 2021

Vibeke Strand, Stanley B. Cohen, Jeffrey R. Curtis, Lixia Zhang, Alan J. Kivitz, Robert W. Levin, Angela Mathis, Erin Connolly-Strong, and Johanna B. Withers Expert Review of...

Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA Blood Test Since Its Launch A Year Ago

Dec 6, 2021

PrismRA enables precision medicine, supports better outcomes, and reduces ineffective utilization of TNFi therapy for rheumatoid arthritis treatment  WALTHAM, Mass. (December 6, 2021) – Scipher Medicine, a precision immunology company matching patients with their most...

Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility

Dec 1, 2021

Christopher Arnell, MBA; Martin Bergman, MD; Dhiman Basu, MD; James T Kenney, RPh, MBA; Johanna B Withers, PhD; Jennifer Logan, PhD; Jeraldine Lim Harashima, MS, CGC; and Erin Connolly-Strong, PhD J Manag Care Spec Pharm. 2021;27(12):1734-42 Abstract: Objectives: To...

America’s Choice Provider Network Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care

Nov 30, 2021

Highlights:PrismRA® Blood Test Supports Personalized Treatment for RA PatientsImproves Clinical Outcomes for Rheumatoid Arthritis (RA) Patients. WALTHAM, Mass. (December 1, 2021) – Scipher Medicine, a precision immunology company matching patients with...

RxParadigm Partners with Scipher Medicine® to Support Medication Utilization, Improve Patient Outcomes, and Lower Costs for Rheumatoid Arthritis Care

Nov 15, 2021

November 15, 2021 – WALTHAM, Mass. – Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced a partnership with RxParadigm, a pharmacy benefit manager company delivering...

Scipher Medicine^® to Present at the Jeffries London Healthcare Conference

Nov 11, 2021

November 11, 2021 – WALTHAM, Mass. – Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer, will...

A molecular signature response classifier to predict inadequate response to tumor necrosis factor-α Inhibitors: the NETWORK-004 Prospective Observational Study

Nov 10, 2021

Stanley Cohen, Alvin F. Wells, Jeffrey R. Curtis, Rajat Dhar, Theodore Mellors, Lixia Zhang, Johanna B. Withers, Alex Jones, Susan D. Ghiassian, Mengran Wang, Erin Connolly-Strong, Sarah Rapisardo, Zoran Gatalica, Dimitrios A. Pappas, Joel M. Kremer, Alif Saleh &...

Scipher Medicine^® to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Nov 10, 2021

November 10, 2021  – WALTHAM, Mass. – Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer will...

Discontinuation of TNFi treatment among Rheumatoid Arthritis patients with a molecular signature of non-response to tumor necrosis factor-ɑ inhibitor therapies

Nov 8, 2021

Jeffrey Curtis, Joel Kremer, Dimitrios Pappas, Lixia Zhang, Erin Connolly-Strong, Johanna Withers, Viatcheslav Akmae and Alif Saleh Abstract: Background: A 23-feature blood-based molecular signature response classifier1 (MSRC) identifies rheumatoid arthritis (RA)...

A molecular signature response classifier predicts the likelihood of non-response to TNF inhibitor therapies in RA at 3 months

Nov 8, 2021

Stanley Cohen, Theodore Mellors, Lixia Zhang, Alex Jones, Erin Connolly-Strong, Dimitrios Pappas, Joel Kremer, Johanna Withers and Viatcheslav Akmae ACR Convergence 2021 Abstract: Background: Most people with rheumatoid arthritis (RA) are prescribed a TNF inhibitor...